 |
26 Diseases |  |
7 Trials |
|
7 Trials |  |
4331 News |  |
| «12...39404142434445464748495051» |
- || Vascepa (icosapent ethyl) / Amarin
Are you the same clueless idiot on AMRN YMB posting your garbage? It's called Vascepa. It's called patent protected. It's called NCE. You want a generic high quality EPA, you'll have to wait until 2029. (Twitter) - Aug 31, 2019
- |||| Vascepa (icosapent ethyl) / Amarin
HEOR: I have a scary Q that may have a scarier answer: What is a normal TG level nowadays? LOL 😲😬🤭😳 @DLBHATTMD @DrMarthaGulati #ESCCongress #cvPrev 😄😄😄 #icosapentethyl (BTW, the draft ICER report indicated it’s very cost-effective currently) (Twitter) - Aug 31, 2019
- ||| Vascepa (icosapent ethyl) / Amarin
Clinical: Icosapent Ethyl in select pts gets a IIa from ESC. JELIS showed similar benefit of regular EPA. unlikely benefit is just from triglyceride lowering so should we use in pts w nl TG? ⬆️💲 in US. Time for someone to make a high quality generic pure EPA. @UTSWCardfellow @UTSWIMchief (Twitter) - Aug 31, 2019
- | Vascepa (icosapent ethyl) / Amarin
If @US_FDA, #EMA, et al approve #Vascepa to treat CVD, that number could be reduced to under 10. #Amarin $AMRN (Twitter) - Aug 31, 2019
- ||||| Vascepa (icosapent ethyl) / Amarin
Clinical: yes, n-3 PUFAs (icosapent ethyl) got a Level IIa “Weight of evidence/opinion is in favor of usefulness/efficacy” Nice entry for icosapent ethyl @ErinMichos @DrMarthaGulati @DLBHATTMD Also, ESC/EAS Dyslipidemia Guidelines have a nice summary for the topic of LDL-C👇#ESCCongress (Twitter) - Aug 31, 2019
- ||||| Vascepa (icosapent ethyl) / Amarin
Clinical: Icosapent Ethyl for high risk patients w/ TG 135-499 in new #ESCCongress dyslipidemia guidelines. Includes primary prev DM pts (inc those w/o end organ damage). @ErinMichos @DrMarthaGulati @DLBHATTMD Reference https://t.co/tskYnE2d8P (Twitter) - Aug 31, 2019
- ||||| Vascepa (icosapent ethyl) / Amarin
Clinical, Video: I look forward to the video. Miss everyone too at #ESCCongress. Yes, I am definitely a fan of carrots 🥕, but high risk secondary prevention patients need intensive LDL lowering with PCSK9 inhibition + statins. If elevated TGs, then icosapent ethyl. New era in #LLT. (Twitter) - Aug 31, 2019
- | Vascepa (icosapent ethyl) / Amarin
Wow! I saw they recommended icosapent ethyl too. Did you have a link to full guidelines? (Twitter) - Aug 31, 2019
- ||| Vascepa (icosapent ethyl) / Amarin
Head-to-Head: As typical ESC way more proactive & evidence based than AHA. ESC referred to icosapent ethyl as “preferred” where AHA basically ignores REDUCE-IT CVOT and says no preference as no head to head study 🤔@DLBHATTMD @skathire @ethanjweiss $AMRN (Twitter) - Aug 31, 2019
- || Vascepa (icosapent ethyl) / Amarin
Great study. Would this be a plausible mechanism for how Vascepa provides cardio protection based on the recent REDUCE-IT trial? (Twitter) - Aug 30, 2019
- || Vascepa (icosapent ethyl) / Amarin
He’s the CEO of the company that has Vascepa; I predict he will win biopharma CEO of the year: Amarin CEO John Thero @business #cardiotwitter #cvPrev @DLBHATTMD @Amarincorp @iamritu @ErinMichos https://t.co/5SkHFmGFWm (Twitter) - Aug 28, 2019
- |||| Vascepa (icosapent ethyl) / Amarin
Drs. @mmillermd1, @CBallantyneMD, @DLBHATTMD & colleagues report the results of REDUCE-IT, which found large, statistically significant reductions in ischemic events w icosapent ethyl across triglyceride tertiles. https://t.co/ilI9Z8u3fB #JACC @chaz_hong @UMmedschool (Twitter) - Aug 28, 2019
- |||| Vascepa (icosapent ethyl) / Amarin
Drs. @mmillermd1, @CBallantyneMD, @DLBHATTMD & colleagues report the results of REDUCE-IT, which found large, statistically significant reductions in ischemic events w icosapent ethyl across triglyceride tertiles. https://t.co/EbwZM0ohOg #JACC @UMBCardiology @UMmedschool (Twitter) - Aug 28, 2019
- ||| Vascepa (icosapent ethyl) / Amarin
This is awesome! Thanks- will look for these #ESCCongress #cvimaging abstracts on EPA eicosapentaenoic -highly purified ethyl ester of EPA, icosapent ethyl https://t.co/JacDYlM1dU (Twitter) - Aug 27, 2019
- || Vascepa (icosapent ethyl) / Amarin
.@DLBHATTMD Congratulations on REDUCE-IT & your major role in educating all on the benefits of icosapent ethyl. https://t.co/LL6zMcA5G3 (Twitter) - Aug 24, 2019
- ||| Vascepa (icosapent ethyl) / Amarin
Drs. @CBallantyneMD, @DLBHATTMD and colleagues report the results of REDUCE-IT, which found large, statistically significant reductions in ischemic events with icosapent ethyl across baseline triglyceride tertiles.… https://t.co/vALdA3PWMc (Twitter) - Aug 23, 2019
- ||| Vascepa (icosapent ethyl) / Amarin, Epanova (eicosapentaenoic acid/docosahexaenoic acid) / AstraZeneca
For me, important questions regarding Strength trial are: 1) Does 4 gm Epanova reach an equivalent plasma EPA level to Vascepa due to its “bioavailability”? 2) Is the perceived increase in LDL-C from DHA due to larger (non-atherogenic) LDL particle size? (Twitter) - Aug 22, 2019
- ||| Vascepa (icosapent ethyl) / Amarin
Late-breaking abstract: For sure. You can sit up front, center with me for any icosapent ethyl presentations. LOL. 🤩🤣🤓 Everyone knows I was 1st row center at ACC during Total Events Reduction. Folks need to keep that latebreaker trend going into AHA. @DLBHATTMD did you hear that 😂👊🤣 jk (Twitter) - Aug 22, 2019
- ||| Vascepa (icosapent ethyl) / Amarin
Biomarker, Clinical: Due to much lower baseline plasma EPA in the “western” population, Reduce-It required 4gm Vascepa to simulate the EPA levels achieved in the Jelis study. 2gm Vascepa, in the Anchor trial, wasn’t enough to achieve significant reductions in several biomarkers. (Twitter) - Aug 22, 2019
- Vascepa (icosapent ethyl) / Amarin
Add-On to Statins in Secondary Prevention: EzetimiBe or Icosapent Ethyl? (204C) - Aug 21, 2019 - Abstract #AHA2019AHA_1313;
There is no abstract associated with this presentation.
- Vascepa (icosapent ethyl) / Amarin
PR.CVS.176. Omega-3 Fatty Acids, EPA and CVD Risk: No Longer a Fish Tale? (204C) - Aug 21, 2019 - Abstract #AHA2019AHA_740;
This session will review the JELIS and REDUCE-IT trials and provide potential mechanisms of benefit. It will also provide benefits of omega-3 fatty acids beyond cardiovascular risk reduction.
- | Vascepa (icosapent ethyl) / Amarin
I see. Ah, icosapent ethyl is Vascepa (Amarin) and Epadel (IP licensed to Amarin outside Japan) https://t.co/S8GIl3yaDM (Twitter) - Aug 21, 2019
- || Vascepa (icosapent ethyl) / Amarin
Yes, as noted the drug is Icosapent Ethyl (AHA does not release the brand name) (Twitter) - Aug 21, 2019
- |||| Vascepa (icosapent ethyl) / Amarin
Drs. @CBallantyneMD, @DLBHATTMD and colleagues report the results of REDUCE-IT, which found large, statistically significant reductions in ischemic events with icosapent ethyl across baseline triglyceride tertiles. https://t.co/75yynjcaNM #JACC (Twitter) - Aug 20, 2019
- ||| Vascepa (icosapent ethyl) / Amarin
Clinical: Outstanding presentation by dr Preston Mason on mechanistic grounds that support clinical effectiveness of Icosapent ethyl in CVD. @DrLuizSilva1 @ProfKausikRay @rauldsf_santos @zorzanelli @marciominame @DLBHATTMD @SABOURETCardio @lansberg @pnatarajanmd https://t.co/rzZmQ7dM6E (Twitter) - Aug 20, 2019
- ||||| Vascepa (icosapent ethyl) / Amarin
New AHA Advisory on Omega-3 Fatty Acids highlights REDUCE-IT study & Icosapent Ethyl for lowering Cardiovascular Disease Risk! @nationallipid @ASPCardio @UMBCardiology @UMmedschool @UMMC @DLBHATTMD @Drlipid @lipiddoc @Amarincorp https://t.co/iS7JnECFby (Twitter) - Aug 20, 2019
- | Vascepa (icosapent ethyl) / Amarin
You must be familiar with the Reduce-it results. #vascepa (Twitter) - Aug 18, 2019
- | Vascepa (icosapent ethyl) / Amarin
Amarin tests Vascepa campaign in preparation for label update https://t.co/BRJx2AIdPW (Twitter) - Aug 16, 2019
- ||| Vascepa (icosapent ethyl) / Amarin
REDUCE-IT showed superb results of icosapent ethyl! I can't wait 4 the indication! @ASPCardio @TheFHFoundation @TheAACE @DrMichaelShapir @dramitkhera @MendedHearts @wiwomenshealth (Twitter) - Aug 16, 2019
- || Vascepa (icosapent ethyl) / Amarin
If you want to save lives and reduce events...the DATA for Vascepa is Crystal Clear....right Dr. Bhatt?😁 (Twitter) - Aug 14, 2019
- | icosapent ethyl / Generic mfg.
Trial initiation date, Trial primary completion date, IO biomarker: OMICC: OMega-3 Fatty Acid for the Immune Modulation of Colorectal Cancer (clinicaltrials.gov) - Aug 14, 2019
P2, N=36, Recruiting, Sponsor: Mingyang Song
It will also provide benefits of omega-3 fatty acids beyond cardiovascular risk reduction. Initiation date: Nov 2018 --> Oct 2019 | Trial primary completion date: Sep 2019 --> Sep 2021
- ||| Vascepa (icosapent ethyl) / Amarin
In Brazil, Vascepa is much more expensive than PCSK 9 inhibitors. Vascepa has to be imported from US. (Twitter) - Aug 14, 2019
- || Vascepa (icosapent ethyl) / Amarin
Agree with @pabeda1, would probably do Rapatha though Vascepa would be reasonable as well. (Twitter) - Aug 14, 2019
- |||| Vascepa (icosapent ethyl) / Amarin
Clinical: Yes in secondary prevention, especially if high risk features like PAD or recent ACS or multiple prior MIs, if LDL-C threshold still >70 mg/dL despite maximal statin+ezetimbe, I would prescribe PCSK9i next. But I am prescribing alot more Vascepa in high risk pts with elevated TGs (Twitter) - Aug 14, 2019
- |||| Vascepa (icosapent ethyl) / Amarin
Clinical: A high risk patient on Crestor 40 mg, Ezetimibe 10 mg , LDL 100 and TG 148. What drug would add first: Vascepa 4 g/day or PCSK9 inhibitors? @DLBHATTMD @ErinMichos @mdmiedema @pabeda1 (Twitter) - Aug 13, 2019
- ||| Vascepa (icosapent ethyl) / Amarin
Clinical: It has already changed my practice. At least 10 high risk patients taking imported Vascepa from US. (Twitter) - Aug 13, 2019
- || Vascepa (icosapent ethyl) / Amarin
FDA event, sNDA: #OTCNewDirections: The @US_FDA #FDA has notified #Amarin that it plans an advisory committee meeting, tentatively scheduled for 14 November, connected to its review of the supplemental new drug application to expand labelling for #Vascepa (icosapent ethyl). (Twitter) - Aug 13, 2019
- || Vascepa (icosapent ethyl) / Amarin
Great to have expert cardiologists’ thoughts on today’s news on icosapent ethyl FDA AdComm. Thanks @khurramn1 (Twitter) - Aug 8, 2019
- | Vascepa (icosapent ethyl) / Amarin
Amarin's Vascepa buzzkill: FDA stalls label review with surprise panel meeting https://t.co/MStMls1YwC (Twitter) - Aug 8, 2019
- ||| The next few months are going to be huge for #cardiovascular disease drug news. #ESC2019 #AHA2019 #Resverlogix #Apabetalone #Esperion #BempedoicAcid #MDCO #Inclisiran #Amarin #Vascepa. $MDCO $RVX $RVXCF $ESPR $AMRN (Twitter) - Aug 8, 2019
- || Vascepa (icosapent ethyl) / Amarin
This should be good @MedscapeCME #IcosapentEthyl #ESC2019 #PrescriptionOmega3 #Omega3 #EPAOmega3 (Twitter) - Aug 7, 2019
- || Vascepa (icosapent ethyl) / Amarin
Thx for sharing! AHA has REDUCE-IT/icosapent ethyl Scientific Statement embargoed and ready for release "very soon". Might bring them in line with ADA SOC. Which would be great. (Twitter) - Aug 4, 2019
- ||| Vascepa (icosapent ethyl) / Amarin
FANTASTIC script growth of Vascepa: $AMRN #VASCEPA #AMRN @Amarincorp #ATH FYI @Novartis $NVS @pfizer $PFE (Twitter) - Aug 2, 2019
- | Vascepa (icosapent ethyl) / Amarin
So... vascepa? (Twitter) - Aug 2, 2019
- | icosapent (MND-2119) / Mochida, Amarin
Trial completion, Trial completion date, Trial primary completion date: Efficacy of MND-2119 in Participants With Hypertriglyceridemia (clinicaltrials.gov) - Aug 1, 2019
P3, N=580, Completed, Sponsor: Mochida Pharmaceutical Company, Ltd.
Initiation date: Nov 2018 --> Oct 2019 | Trial primary completion date: Sep 2019 --> Sep 2021 Recruiting --> Completed | Trial completion date: Oct 2019 --> Jun 2019 | Trial primary completion date: Oct 2019 --> Jun 2019
- || Vascepa (icosapent ethyl) / Amarin
.@DLBHATTMD and Dr. Preston Mason together in Paris, France speaking on icosapent ethyl sounds great. 🇫🇷 (Twitter) - Aug 1, 2019
- ||| Vascepa (icosapent ethyl) / Amarin
As with Vascepa and REDUCE-IT I think it will be crucial to determine the dose- response relationship as well as the mechanism ( are the benefits also seen in non ishcaemic #Heartfailure ) (Twitter) - Jul 31, 2019
- | Vascepa (icosapent ethyl) / Amarin
Amarin CEO: When it comes to Vascepa expansion, 'we can do this on our own' https://t.co/1UHjSGoil7 (Twitter) - Jul 31, 2019
- || Vascepa (icosapent ethyl) / Amarin
Vascepa sales 🐟 (Twitter) - Jul 31, 2019
- ||| Vascepa (icosapent ethyl) / Amarin
Clinical: The PI of MARINE and now the Global PI of REDUCE-IT have likewise done as told, as they were paid for, backing up the exaggerated “placebo-corrected” data that makes Vascepa look far more effective than it is. And it’s very common, Duane. All PIs do this to varying degrees. (Twitter) - Jul 28, 2019